Idiopathic nephrotic syndrome is the most common chronic glomerular disease in children. At least 20 % of children with this syndrome show frequent relapses and/or steroid dependence during or after immunosuppressive therapies, a condition defined as complicated frequently relapsing/steroid-dependent nephrotic syndrome (FRNS/SDNS). Approximately 1–3 % of children with idiopathic nephrotic syndrome are resistant to steroids and all immunosuppressive agents, a condition defined as refractory steroid-resistant nephrotic syndrome (SRNS); these SRNS children have a high risk of end-stage renal failure. Rituximab, a chimeric anti-CD20 monoclonal antibody, has been shown to be effective for patients with complicated FRNS/SDNS and refractory SRNS. This review describes the recent results of rituximab treatment applied to pediatric nephrotic syndrome, as well as those of our recent study, a multicenter, double-blind, randomized, placebo-controlled trial of rituximab for childhood-onset complicated FRNS/SDNS (RCRNS01). The overall efficacy and safety of rituximab for this disease are discussed.
International Study of Kidney Disease in Children. Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children. Kidney Int. 1978;13:159–65. CrossRef
International Study of Kidney Disease in Children. The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. J Pediatr. 1981;98:561–4. CrossRef
Hodson EM, Willis NS, Craig JC. Non-corticosteroid treatment for nephrotic syndrome in children. Cochrane Database Syst Rev. 2013. Art. No. CD002290, Issue 10. doi: 10.1002/14651858.CD002290.pub4.
Hodson EM, Willis NS, Craig JC. Interventions for idiopathic steroid-resistant nephrotic syndrome in children. Cochrane Database Syst Rev 2010. Art. No. CD003594, Issue 11. doi: 10.1002/14651858.CD003594.pub4.
Ishikura K, Yoshikawa N, Hattori S, et al.; For Japanese Study Group of Renal Disease in Children. Treatment with microemulsified cyclosporine in children with frequently relapsing nephrotic syndrome. Nephrol Dial Transpl. 2010;25:3956–62.
Hamasaki Y, Yoshikawa N, Hattori S, et al.; Japanese Study Group of Renal Disease. Cyclosporine and steroid therapy in children with steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2009;24:2177–85.
Yabu JM, Ho B, Scandling JD, Vincenti F. Rituximab failed to improve nephrotic syndrome in renal transplant patients with recurrent focal segmental glomerulosclerosis. Am J Transplant. 2008;8:222–7. PubMed
Ruggenenti P, Ruggiero B, Cravedi P, et al.; Rituximab in Nephrotic Syndrome of Steroid-Dependent or Frequently Relapsing Minimal Change Disease Or Focal Segmental Glomerulosclerosis (NEMO) Study Group. Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. J Am Soc Nephrol. 2014;25:850–63.
Ahn YH, Kang HG, Kim SH, et al. Efficacy and safety of rituximab in children with refractory nephrotic syndrome; a multicenter clinical trial. (Abstract) Kidney Res Clin Pract. 2014;33:A1. CrossRef
Rituxan ® Injection 10 mg/mL Early Postmarketing Phase Vigilance Report, http://www.zenyaku.co.jp/iyaku/doctor/rituxan/survey/nephrotic/pdf/report_150601.pdf. Accessed 10 May 2016.
Current status of patient registration for Rituxan ® Injection drug use-results survey [complicated nephrotic syndrome (frequently relapsing and steroid-dependent)] http://www.zenyaku.co.jp/iyaku/doctor/rituxan/survey/nephrotic/pdf/currentstatus_160427.pdf. Accessed 10 May 2016.
Bonanni A, Rossi R, Murtas C, et al. Low-dose ofatumumab for rituximab-resistant nephrotic syndrome. BMJ Case Rep. 2015;16:2015.
- Rituximab for nephrotic syndrome in children
- Springer Japan
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II